Heron Therapeutics | HRTX - Pre Tax Profit


Heron Therapeutics reported $-2.95M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Eisai JPY -7.94B 29.94B Mar/2026
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 571K 8.95M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Veracyte USD 29.97M 10.66M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026